Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Juvisync in Type 2 Diabetes Mellitus
NCT01678820Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Primary completion
- Nov 2013
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin + simvastatin in type 2 diabetes mellitus (T2DM) and hypercholesterolemia, sponsored by Merck & Co. Started Oct 2012; status: terminated.
02
Drugs
sitagliptin + simvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on NCT01678820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01678820.